Clinical Trial Update: Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update from Peking University investigates immunotherapy with hypofractionated concurrent chemoradiotherapy followed by immunotherapy f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING